Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
Launched by AESCULAP AG · Sep 5, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effectiveness of a new type of suture called SYMMCORA® compared to a traditional suture, V-Loc®, in women undergoing laparoscopic total hysterectomy, which is a minimally invasive surgery to remove the uterus. The main goal is to see if the SYMMCORA® suture helps doctors close the vaginal cuff (the area at the top of the vagina after the uterus is removed) more quickly without causing more complications. Both sutures are approved for use, and this study will take place in a regular hospital setting where patients will be randomly assigned to receive one of the two sutures.
To take part in this trial, you must be a woman aged 18 or older who is scheduled for an elective laparoscopic total hysterectomy. If you have had an emergency surgery, are undergoing open surgery, have certain allergies, or are currently taking specific medications, you may not be eligible. Participants will not experience any extra procedures or burdens during their treatment; the only difference is the type of suture used during the surgery. This study aims to find the best option for closing the vaginal cuff efficiently and safely.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Females undergoing an elective, laparoscopic total hysterectomy
- • Age ≥ 18 years
- • Written informed consent
- Exclusion Criteria:
- • Emergency surgery
- • Open surgery
- • Patients undergone immunosuppressive drug treatment within the prior 6 months
- • Patients with hypersensitivity or allergy to the suture material.
- • Participation in another clinical study
- • Non-compliance of patient
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manresa, Barcelona, Spain
Frankfurt/Main, Hessen, Germany
Patients applied
Trial Officials
Amadeus Hornemann, Prof. Dr.
Principal Investigator
Klinikum Sachsenhausen der DGD
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported